Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases

Clin Lung Cancer. 2019 May;20(3):e247-e250. doi: 10.1016/j.cllc.2018.12.006. Epub 2018 Dec 19.

Authors

Michael Schwarz¹, Florian Kocher², Dora Niedersuess-Beke¹, Jakob Rudzki², Maximilian Hochmair³, Gerlig Widmann⁴, Wolfgang Hilbe¹, Andreas Pircher⁵

Affiliations

¹ Department of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria.
² Department of Hematology and Oncology, Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria.
³ Respiratory Oncology Unit, Otto-Wagner Hospital, Vienna, Austria.
⁴ Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria.
⁵ Department of Hematology and Oncology, Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: andreas.pircher@i-med.ac.at.

PMID: 30635258
DOI: 10.1016/j.cllc.2018.12.006

No abstract available

Keywords: Case report; Checkpoint inhibitors; Glucocorticoids; Immune checkpoint blockade; Pneumonitis.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Carcinoma, Non-Small-Cell Lung / complications
Carcinoma, Non-Small-Cell Lung / drug therapy*
Drug Resistance, Neoplasm
Drug-Related Side Effects and Adverse Reactions / diagnosis*
Fatal Outcome
Humans
Immunotherapy / adverse effects
Immunotherapy / methods*
Lung Neoplasms / complications
Lung Neoplasms / drug therapy*
Male
Nivolumab / adverse effects
Nivolumab / therapeutic use*
Pneumocystis carinii / physiology*
Pneumonia, Pneumocystis / diagnosis*
Pneumonia, Pneumocystis / etiology
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Respiratory Insufficiency / diagnosis*

Substances

Antineoplastic Agents
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab